

STEPHEN D. BETSCHEL^{1*}, WILLIAM R. LUMRY², TIMOTHY J. CRAIG³, ANDREA ZANICHELLI⁴, EMEL AYGÖREN-PÜRSÜN⁵, JOHN T. ANDERSON⁶, MARKUS MAGERL⁷, RAFFI TACHDJIAN⁸, ALEENA BANERJI⁹, CLAIRE VANEENWYK¹⁰, THEODORA COHEN¹⁰, CHRISTOPHER MORABITO¹⁰, MICHIIRO HIDE¹¹, MARK RIEDL¹²

1. University of Toronto, Toronto, ON, 2. AARA Research Center, Dallas, TX, USA, 3. Penn State Health Allergy, Asthma and Immunology, Hershey, PA, USA, 4. Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milano, Italy & Unità Operativa di Medicina, Centro Angioedema, I.R.C.C.S. Policlinico San Donato, San Donato Milanese, Milano, Italy, 5. Goethe-Universität, Frankfurt am Main, Germany, 6. AllerVie Health, Birmingham, AL, USA, 7. Universitätsmedizin, Berlin, Germany, 8. UCLA School of Medicine, Los Angeles, Los Angeles, CA, USA, 9. Massachusetts General Hospital, Boston, MA, USA, 10. Astria Therapeutics, Boston, MA, USA, 11. Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, 12. University of California-San Diego, San Diego, CA, USA

*PRESENTING AUTHOR



SUMMARY

1

NAVENIBART IS AN INVESTIGATIONAL HUMANIZED IGG1 KAPPA LIGHT CHAIN MONOCLONAL ANTIBODY DESIGNED TO BE A HIGHLY POTENT AND SPECIFIC PLASMA KALLIKREIN INHIBITOR. INITIAL RESULTS FROM CLINICAL TRIALS WITH HEALTHY PARTICIPANTS AND PARTICIPANTS WITH HAE-C1INH DEMONSTRATES POTENT PHARMACODYNAMIC ACTIVITY AND A PHARMACOKINETIC PROFILE THAT SUPPORTS Q3M AND Q6M ADMINISTRATION.

2

IN PHASE 1B/2, THE ALPHA-STAR TRIAL IN PARTICIPANTS WITH HAE-C1INH, NAVENIBART TREATMENT DEMONSTRATES RAPID AND CLINICALLY-RELEVANT REDUCTIONS IN FREQUENCY OF HAE ATTACKS, REDUCTIONS IN THE NUMBER OF SEVERE ATTACKS, AND NUMBER OF HAE ATTACKS REQUIRING ON-DEMAND TREATMENT ALONG WITH A FAVORABLE SAFETY AND TOLERABILITY PROFILE.

3

ALPHA-ORBIT (NCT06842823) IS A PIVOTAL PHASE 3, MULTICENTER STUDY DESIGNED TO EVALUATE THE EFFICACY AND SAFETY OF NAVENIBART ADMINISTERED EVERY 3 OR 6 MONTHS FOR LONG-TERM PREVENTION OF HAE ATTACKS IN PARTICIPANTS WITH HAE-C1INH. THE STUDY INCLUDES A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED COHORT IN ADULTS AND AN OPEN-LABEL COHORT IN ADOLESCENTS.

OBJECTIVE

Describe the design of ALPHA-ORBIT (NCT06842823), a Phase 3, multicenter trial evaluating the efficacy and safety of an investigational therapeutic navenibart in preventing HAE attacks in participants with HAE-C1INH. The trial includes a randomized, double-blind, placebo-controlled portion in adults and an open-label portion in adolescents.

INTRODUCTION

- HAE is a rare autosomal dominant genetic disease characterized by severe, recurrent, unpredictable, often painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway.
- Most HAE-C1INH cases are caused by mutations in the *SERPING1* gene that reduce the level or function of C1-esterase inhibitor protein (C1-INH) encoded by this gene, resulting in unregulated plasma kallikrein activity.
- Navenibart is a humanized IgG1 kappa light chain monoclonal antibody designed to be a highly potent and specific inhibitor of plasma kallikrein, thereby inhibiting the production of bradykinin.
- The Fc domain of navenibart incorporates a 3–amino acid YTE modification designed to enhance pH-dependent neonatal Fc receptor binding and extend circulating half-life.
- Results of a Phase 1b/2 trial demonstrate that navenibart is well-tolerated after 1 or 2 doses and reduced attack frequency, severity, and rescue medication use for at least 6 months.
- Navenibart has the potential to become an effective and safe long-term prophylaxis treatment for HAE-C1INH, with administration every 3 or 6 months.

METHODS

Figure 1. ALPHA-ORBIT (NCT06842823) - Trial Schema




Table 1. ALPHA-ORBIT, a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Trial population	Adults (≥ 18 years old); Adolescents (≥12 to <18 years old) with HAE-C1INH
Location(s)	Global, Multicenter
Randomization	Adults (n=135) – 3:3:3:2 Adolescents (n=10) – n/a - all assigned to navenibart
Dosing	Adults: Two subcutaneous (SC) doses of Investigational Product (navenibart or placebo) at Day 1 and Day 91 Adolescents: Two SC doses of navenibart at Day 1 and one dose on Day 91
Assessment Frequency	Monthly, through 3 months after the last dose of IP
Assessments	HAE attack information (efficacy); safety, pharmacokinetics, pharmacodynamics, immunogenicity, biomarkers, and quality-of-life evaluations

RESULTS

Primary Endpoint

Adults and adolescents: Number of time-normalized, investigator-confirmed HAE attacks during the 6-month Treatment Period
Adolescents: Safety

Secondary Endpoints

- Number of moderate or severe investigator-confirmed HAE attacks during the 6-month Treatment Period
- Number of investigator-confirmed HAE attacks that require on-demand treatment during the 6-month Treatment Period
- Percent reduction in monthly investigator-confirmed HAE attacks in the 6-month Treatment Period versus the Run-In Period
- Time to first investigator-confirmed HAE attack after first dose
- Number of participants responding to treatment, defined as a ≥50%, ≥70%, or ≥90% reduction from the Run-In Period in investigator-confirmed HAE attack rate compared to placebo during the 6-month Treatment Period
- Number of participants with no investigator-confirmed HAE attacks during the 6-month Treatment Period
- Change from baseline (Day 1) in the Angioedema Quality of Life questionnaire Total Score
- Incidence of treatment-emergent adverse events

Key Inclusion Criteria

- Documented diagnosis of HAE-C1INH (Type 1 or Type 2), including:
 - documented clinical history consistent with HAE-C1INH
 - age at reported onset of first angioedema symptoms ≤ 30 years of age, or a family history consistent with HAE-C1INH
 - lab findings consistent with HAE-C1INH
- Participants will be eligible to exit the Run-In Period and enter the Treatment Period if they meet both of the following criteria:
 - participated in the Run-In Period for ≥ 1 month
 - experienced a total of 2 or more investigator-confirmed HAE attacks during the Run-In-Period

Key Exclusion Criteria

- Any exposure to an investigational drug within 5 half-lives before informed consent
- Has ever received gene editing therapy
- Long-term prophylaxis must not have been used for the following durations before the first day of run-in: lanadelumab within 90 days; berotralstat within 21 days; plasma-derived C1INH for LTP within 14 days; androgens within 3 days; all other long-term prophylaxis require consultation with the medical monitor
- Diagnosis of another form of chronic angioedema, such as acquired C1-INH deficiency, HAE with normal C1-INH, idiopathic angioedema, or angioedema associated with urticaria

CONCLUSIONS

ALPHA-ORBIT will provide pivotal evidence on the efficacy, durability, and safety of navenibart in hereditary angioedema. Results are anticipated to inform a potential new standard of care.

Acknowledgments: We would like to thank the patients, families, investigators and study teams for dedication and partnership.